Monitoring treatment response using serial PTX3 levels in chronic and invasive pulmonary aspergillosis.

BACKGROUND Pentraxin 3 (PTX3) is an innate immune biomarker involved in host defense against Aspergillus species. While elevated PTX3 levels have been observed in various infection states, its utility in monitoring treatment response in pulmonary aspergillosis remains underexplored. METHODS We assessed serial PTX3 levels in total 216 patients with chronic pulmonary aspergillosis (CPA, n = 48) and invasive pulmonary aspergillosis (IPA, n = 48) before and after antifungal therapy. Comparative groups included controls (n = 69), COVID-19 patients (n = 36), and allergic bronchopulmonary aspergillosis (ABPA, n = 15). Serum PTX3 concentrations were measured by ELISA and analyzed in relation to treatment response. Neutrophil extracellular trap (NET) formation under various stimuli was evaluated and correlated with PTX3 levels to explore immune activation patterns. RESULTS PTX3 levels were significantly elevated in CPA and IPA compared to controls. Among patients with serial samples, PTX3 levels declined significantly in favorable responders (from 299.0 [119.5-477.0] to 138.3 [80.9-386.1] pg/mL; p < 0.05), but increased in unfavorable responders (from 177.1 [117.8-318.8] to 243.0 [169.5-488.4] pg/mL; p < 0.05). PTX3 changes correlated with disease course and NET responses in a phenotype-specific manner. CONCLUSION Serial measurement of PTX3 may serve as a useful biomarker for monitoring treatment response in pulmonary aspergillosis. PTX3 dynamics reflect underlying immune activity and may aid in identifying disease progression or relapse.

• Publication year

  2025

• Venue

  Clinica chimica acta; international journal of clinical chemistry

• Publication date

  2025-08-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cca.2025.120553PMID 40829730
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pentraxin-3 as a novel prognostic biomarker in non-neutropenic invasive pulmonary aspergillosis patients

  2025cited by this paper
• Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients: An Official American Thoracic Society Clinical Practice Guideline

  2024cited by this paper
• Pentraxin-3 (PTX-3) as a potential biomarker for predicting death in hospitalized patients with COVID-19

  2024cited by this paper
• Interplay between host humoral pattern recognition molecules controls undue immune responses against Aspergillus fumigatus

  2024cited by this paper
• Long pentraxin 3 as a marker of COVID-19 severity: evidences and perspectives

  2022cited by this paper
• Outcomes of surgery for different types of chronic pulmonary aspergillosis: results from a single-center, retrospective cohort study

  2022cited by this paper
• Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement

  2022cited by this paper
• COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis

  2022cited by this paper
• The emerging role of neutrophil extracellular traps in fungal infection

  2022cited by this paper
• Multicenter analysis of neutrophil extracellular trap dysregulation in adult and pediatric COVID-19

  2022cited by this paper
• When to change treatment of acute invasive aspergillosis: an expert viewpoint

  2021cited by this paper
• Circulating pentraxin 3 in severe COVID‐19 or other pulmonary sepsis

  2021cited by this paper
• Increased peripheral blood neutrophil activation phenotypes and NETosis in critically ill COVID-19 patients: a case series and review of the literature

  2021cited by this paper
• Surgical resection for patients with pulmonary aspergillosis in the national inpatient sample

  2021cited by this paper
• The role of pentraxin3 in plasma and bronchoalveolar lavage fluid in COPD patients with invasive pulmonary aspergillosis

  2021cited by this paper
• Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021

  2021cited by this paper
• Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19

  2020cited by this paper
• Pentraxin-3 and endothelial dysfunction.

  2019cited by this paper
• Pentraxin 3 in bronchoalveolar lavage fluid and plasma in non-neutropenic patients with pulmonary aspergillosis.

  2019cited by this paper
• Synthesis of Human Neutrophil Extracellular Traps Contributes to Angiopoietin-Mediated In Vitro Proinflammatory and Proangiogenic Activities

  2018cited by this paper
• Pentraxin 3 Gene Polymorphisms and Pulmonary Aspergillosis in Chronic Obstructive Pulmonary Disease Patients

  2018cited by this paper
• Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

  2016cited by this paper
• PTX3 is an extrinsic oncosuppressor regulating complement-dependent inflammation in cancer.

  2015cited by this paper
• Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management

  2015cited by this paper
• Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation.

  2014cited by this paper
• Host-protective effect of circulating pentraxin 3 (PTX3) and complex formation with neutrophil extracellular traps

  2012cited by this paper
• Regulation of leukocyte recruitment by the long pentraxin PTX3

  2010cited by this paper
• Role of complement and Fc{gamma} receptors in the protective activity of the long pentraxin PTX3 against Aspergillus fumigatus.

  2010cited by this paper
• The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps

  2007cited by this paper

• Synergistic effects of S100 calcium-binding protein A12 combined with Pentraxin 3 in invasive pulmonary aspergillosis and their clinical application prospects

  2026cites this paper
• Harnessing host-derived biomarkers for personalized diagnosis of invasive fungal infections

  2025cites this paper